Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They should hire a college student looking for some extra cash to help them.
However, any smart college student would reject an offer due to liability.
"According to ClinicalTrials.gov - there hasn't been any research posted."
Not sure what you're looking at. As noted, a Phase 1 trial is primarily to determine safety.
"This trial is a Phase I open-label safety study of Prolanta™, a recombinant analog of the human prolactin protein with a single amino acid substitution to create an antagonist of the prolactin receptor."
Estimated Enrollment: 18
Study Start Date: February 2016
Estimated Study Completion Date: January 2018
Estimated Primary Completion Date: December 2017 (Final data collection date for primary outcome measure)
https://clinicaltrials.gov/ct2/show/NCT02534922?term=prolanta&rank=1
"The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer."
"The FDA has also approved the designation of Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow reduced filing fees, federal tax credits and marketing exclusivity by the FDA."
https://oncolixbio.com/
Those things don't say anything about the drug's efficacy, only its intended purpose, but they suggest a legitimate effort to develop a drug.
"This is pretty odd.
The patent was assigned from ADVANCED ENVIRONMENTAL PETROLEUM PRODUCERS, INC. ONCOLIX, INC. - to PURITAN PARTNERS LLC on 08/07/2017."
It is odd. It looks like the US patent portfolio of Oncolix was used as part of a security agreement, but it definitely needs more research.
http://legacy-assignments.uspto.gov/assignments/assignment-pat-43214-671.pdf
https://www.lawinsider.com/contracts/1mXmBfV3CO9xqBap3wceaP/electric-vehicle-research-corp/1584137/2017-08-09
An S-1 filing by Oncolix in August included the above as Exhibits.
https://www.sec.gov/Archives/edgar/data/1584137/000147793217004228/aepp_s1.htm
After several Amendments it was declared Effective yesterday.
Too much digging to be done for this old man.
Conspiracy thinking less likely with greater news media literacy, study suggests
Date: November 30, 2017
Source: University of Illinois at Urbana-Champaign
https://www.sciencedaily.com/releases/2017/11/171130150424.htm
Summary:
The more you know about the news media and how it works, the less likely you are to believe conspiracy theories - even ones you might find politically tempting. The connection held true overall even where conspiracy theories resonated with an individual's political beliefs.
The more you know about the news media and how it works, the less likely you are to believe conspiracy theories -- even ones you might find politically tempting.
That's the conclusion University of Illinois journalism professor Stephanie Craft and her research colleagues reached in a study being published next month in the journal Communication and the Public.
The researchers surveyed nearly 400 participants online in spring 2016 to gauge how their news media literacy -- measured as a combination of news media knowledge and psychological traits connected with processing news messages -- might relate to their endorsement of conspiracy theories.
The researchers found that "individuals who give credence to conspiracy theories know comparatively little about how the news media work." They also found that "the greater one's knowledge about the news media -- from the kinds of news covered, to the commercial context in which news is produced, to the effects on public opinion news can have -- the less likely one will fall prey to conspiracy theories."
Craft believes their research is the first to make that connection. But what Craft found even more interesting, and encouraging, were findings that showed it applied even where conspiracy theories resonated with an individual's political beliefs.
The study asked participants about the strength of their belief in any of 10 conspiracy theories, split evenly between those associated with liberal and conservative perspectives. It also asked separate questions to determine participants' ideological beliefs.
The researchers found that liberals with higher news media literacy were less likely to believe any or all of the five liberal conspiracy theories -- among them that the federal government knew about the 9/11 terrorist attacks beforehand, that Republicans stole the 2004 presidential election through voter fraud in Ohio, and that there's a link between childhood vaccines and autism.
Likewise, conservatives with higher news media literacy were less likely to believe five conspiracy theories commonly associated with conservatives -- among them that Barack Obama was not born in the U.S., that global warming is a hoax, and that the 2010 health care law authorized government panels to make end-of-life decisions for people on Medicare.
Co-authors of the study are Seth Ashley, a professor of communication at Boise State University, and Adam Maksl, a professor of journalism and media at Indiana University Southeast. All three co-authors previously worked together to develop the measure of news media literacy used in the study and have done additional work on the topic.
The 397 participants in the survey were recruited using Amazon's Mechanical Turk system. Based on a measure of political ideology, 195 were identified as liberal, 126 as conservative and 76 could not be identified as either liberal or conservative.
Contrary to popular conception, believing in conspiracy theories "is not the sole province of the proverbial nut-job," the researchers write. Conspiracy theories "are almost by definition 'good' (i.e., enticing) stories," and even reasonable individuals can buy into theories not supported by the best evidence, they note. "The power of a compelling narrative and one's pre-existing biases are often no match for conflicting information."
But given those factors and others that might play a part in conspiracy theory endorsement, Craft said she was encouraged to find that promoting greater news media literacy might have a small-but-significant effect.
"To the extent that we've hit on one thing that seems to matter in a nontrivial kind of way, that represents some sort of progress," she said.
It's also a piece "we can do something about," she said, rather than trying to change set beliefs, alter news habits or complain about "fake news."
Educators can promote news media literacy in schools, Craft said, and journalists can play a part "by being more open about how they do what they do."
"One of the tricky areas for people in the news literacy area is you want to encourage skepticism, you want to encourage people to be actively thinking about news, not just consuming it like candy," she said. "But there's kind of a fine line between being a skeptical news consumer and a cynical one, where the cynical one would just think, 'Oh well, they all make stuff up, they all do it, it's all wrong.' That doesn't serve anyone, either."
Story Source:
Materials
provided by University of Illinois at Urbana-Champaign. Note: Content may be edited for style and length.
Journal Reference:
Stephanie Craft, Seth Ashley, Adam Maksl. News media literacy and conspiracy theory endorsement. Communication and the Public, 2017; 205704731772553 DOI: 10.1177/2057047317725539
https://www.sciencedaily.com/releases/2017/11/171130150424.htm
Rainwater harvesting : Resource guaranteed for the underprivileged
Wednesday, March 22, 2017 - 01:00
Today is World Water Day. The Daily News sat down with Executive Director of the Lanka Rain Water Harvesting Forum Dr. Tanuja Ariyananda to discuss what her organization does to combat water scarcity in Sri Lanka. As the world undergoes climate change, seasonal rainfall is becoming more erratic, further challenging scientists and policymakers who wish to ensure water availability for everyone. One such manner of guaranteeing access to water is through rainwater harvesting, whereby rain is captured in large above-ground tanks. Dr. Ariyananda’s organization has set up thousands of these systems to combat drinking water scarcity for people throughout the island.
...
...
more
http://www.dailynews.lk/2017/03/22/features/111126/rainwater-harvesting-resource-guaranteed-underprivileged
Indo-Lanka MoU to construct 3,000 rainwater harvesting systems
Saturday, January 14, 2017 - 01:00
India and Sri Lanka yesterday signed an MoU to construct 3,000 rainwater harvesting systems at a cost of Rs. 300 million in the Jaffna District.
The project envisages construction of 3,000 rainwater harvesting systems for 3,000 households in selected divisions of the Jaffna District.
...
more
http://www.dailynews.lk/2017/01/14/local/104674/indo-lanka-mou-construct-3000-rainwater-harvesting-systems
More
http://www.dailynews.lk/search/node/Rainwater
They are PR'ing what is in reality somoene else's business activity?
HIHI constantly puts out PR's about activities in a development they have no ownership interest in.
Agrimed, a private company completely unrelated to UNVC is the only subject discussed on the UNVC board such that it is now the only thing really "on topic"
In other words, other businesses legitimate activities soon bcome assumed to be yours, even if they aren't. "We diddn't say it was OUR activity in the news"
COMMERCIAL BANK OF CEYLON PLC
Resolution adopted by the Board of Directors of
Commercial Bank of Ceylon PLC (Registration No. PQ
116) under Section 4 of the Recovery of Loans by Banks
(Special Provisions) Act No. 4 of 1990.
Account No. 6015670
Loan Account Nos. 6133, 21594, 22953 & 24287
PANAMBARA ARATCHILAGE RANIL SOMAWEERA
SOLE PROPRIETOR OF
SPEEDWAY METAL INDUSTRIES and
BIG APPLE HOLDINGS
At a meeting held on 18th June 2010, the Board of
Directors of Commercial Bank of Ceylon PLC resolved
specially and unanimously as follows:-
WHEREAS PANAMBARA ARATCHILAGE RANIL
SOMAWEERA carrying on business as the Sole
Proprietor under the name and style of SPEEDWAY
METAL INDUSTRIES as the Obligor has made default
in the payment due on Bond Nos. 367 dated 8th
September 1989, 475 dated 25th January 1991 and
1348 dated 31st March 1994 all attested by R. K.
Jayawardena, Notary Public of Colombo in favour of
Commercial Bank of Ceylon Limited now known as
Commercial Bank of Ceylon PLC (the lands morefully
described in the First and Second Schedules hereto).
“WHEREAS PANAMBARA ARATCHILAGE RANIL
SOMAWEERA carrying on business as the Sole
Proprietor under the name and style of BIG APPLE
HOLDINGS as the Obligor has made default in the
payment due on Bond No. 466 dated 22nd March 1996
attested by L. R. Witharana, Notary Public of Colombo
in favour of Commercial Bank of Ceylon Limited now
known as Commercial Bank of Ceylon PLC (the land
morefully described in the Second Schedule hereto) and
there is now due and owing to the Commercial Bank of
Ceylon PLC as at 15th January 2010 a sum of RUPEES
THIRTY SEVEN MILLION SIX HUNDRED AND NINETY
SIX THOUSAND TWO HUNDRED AND FIFTY THREE
(Rs. 37,696,253/-) on the said Bonds and the Board of
Directors of Commercial Bank of Ceylon PLC under the
powers vested by Recovery of Loans by Banks (Special
Provisions) Act No. 4 of 1990 do hereby resolve that
the property and premises morefully described in the
Schedules hereto and mortgaged to the Commercial
Bank of Ceylon PLC by the said Bond Nos. 367, 475,
1348 and 466 be sold by Public Auction by Mr. L. B.
Senanayake, Licensed Auctioneer of No. 99, Hulftsdorp
Street, Colombo 12 for the recovery of the said sum of
Rupees Thirty Seven Million Six Hundred And Ninety
Six Thousand Two Hundred And Fifty Three (Rs.
37,696,253/-) with further interest on a sum of Rs.
7,401,265/- at 22% per annum from 16th January 2010
to date of sale together with costs of Advertising and
any other charges incurred less payments (if any) since
received”.
THE FIRST SCHEDULE ABOVE REFERRED TO
All that divided allotment of land marked Lot 144A on
the Survey Plan bearing No. 1967 hereinafter referred
to called Kandawala Estate together with the trees,
plantations and everything else standing thereon
bearing assessment No. 20A, 4th Cross Lane, Hindu
College square off Borupana Road at Ratmalana in the
Palle Pattu of Salpiti Korale in the District of Colombo
Western Province and which said allotment of land
marked Lot 144A is bounded on the North by Lot 146
on the aforesaid plan bearing No. 33 on the East by Lot
145 on the aforesaid plan bearing No. 33, on the South
by Lot 144B on the aforesaid Survey Plan Bearing No.
1967 on the West by Lot 139 on the aforesaid Survey
Plan No. 33 which was private Road and is now called
4th Cross Lane, Hindu College Square which is now a
road maintained by the Dehiwela-Mount Lavinia
Municipal Council containing in extent Twenty Perches
(A0-R0-P20) as per the Survey Plan No. 1967 dated
7th April 1976 made by K.K. Thirunavukarasu Licensed
Surveyor and Registered under Volume/Folio M 1205/
46 at the Delkanda-Nugegoda Land Registry.
THE SECOND SCHEDULE ABOVE REFERRED TO
All that divided and defined allotment of land marked
Lot 3 in Survey Plan No. 175 dated 15th November 1957
made by W. R. B. Silva Licensed Surveyor (erroneously
described as Lot B3 in a copy of this same Plan) of the
land called Delgahawatta Madanagahawatta alias
Ambagahawatta with the buildings constructed and
everything standing thereon bearing Assessment No. 7
off Waidya Road, situated at Kalubowila West within
the Municipal Council Limits of Dehiwela-Mount Lavinia
in the Palle Pattu of Salpiti Korale in the District of
Colombo Western Province and which said Lot 3 is
bounded on the North by Lot 4 (erroneously described
as Lot B4 in a copy of the said Plan No. 175) of the
same land on the East by Reservation for road 20 feet
wide on the South by Lot 2 (erroneously described as
Lot B2 in a copy of the said Plan No. 175) of the same
land and on the West by Lot 9 (erroneously described
as Lot B9 in a copy of the said Plan No. 175) and
property of H. J. Jayawardena and containing in extent
Twenty Perches (A0-R0-P20) according to the said Plan
No. 175 together with the full and free right liberty leave
and license of way and passage for both foot and
vehicular traffic in along and over the reservation for a
road Twenty Feet wide depicted in the said Plan No.
175 and Registered under Volume/Folio M 808/138 at
the Delkanda-Nugegoda Land Registry.
MRS. R. R. DUNUWILLE
COMPANY SECRETARY
http://pdfs.island.lk/2010/11/24/p13.pdf
Boom and Bust - The Island
pdfs.island.lk/2010/11/24/p13.pdf
24 Nov 2010 - incorporated in the Democratic Socialist Republic of Sri Lanka under the. Companies Act No. 17 of 1982 .... 1,676,148/33) of lawful money of Sri Lanka being the total amount outstanding on the said Bonds and the Board of ... PANAMBARA ARATCHILAGE RANIL SOMAWEERA. SOLE PROPRIETOR OF.
Puritan Partners LLC - Chris Notarangelo
Old patents picked up by Puritan Partners LLC.
http://www.google.co.zm/patents/US7339027
http://www.google.com.pg/patents/US20030022833
http://www.google.com.gi/patents/US8648046
Chris Notarangelo
Owner @ Puritan Partners RE Investments (aka Puritan Partners LLC)
Looks like he's just a contractor, finding a different way to scam (patent pumps)? He has absolutely nothing to do with the medical field.
What 5 cent penny stock looks good? Lol
Im interested in the planned clinicals but this company has a long ways to go before being considered an investment
Wrong... phase 1 is the riskiest phase of clinicals and over 80% of ovarian cancer patients are diagnosed in advances stages anyway
This cohort has been heavily treated and are unresponsive. This is the profile to test where there is little to ko downside.
According to ClinicalTrials.gov - there hasn't been any research posted.
Pretty odd for Phase 1 of the clinical studies that started in 2015 not to have any published research in 2 years.
Patent number 7,115,556 was published in 2006 and there hasn't been much progress.
This is pretty odd.
The patent was assigned from ADVANCED ENVIRONMENTAL PETROLEUM PRODUCERS, INC. ONCOLIX, INC. - to PURITAN PARTNERS LLC on 08/07/2017.
It looks like some research is needed - so far it doesn't look great.
IG
So do they expect to "make" the water in some places and send it to other places?
Not for Phase I testing. You're supposed to use healthy patients only.
And use very low doses, sub-clinical doses. Dosages at which your product is not even expected to have any curative effects.
In Phase I trials, you're merely looking for adverse effects and side effects.
It is also unethical to claim any results before the trial is over and all the data has been compiled.
But don't forget that, according to RAKR own brochure, the Air-to-Water™ windmill works best at 80% ambient humidity.
So, in the middle of a torrential downpour, that's the absolute best time to "make" water. Sri Lanka does experience a month-long annual monsoon ...
Not unusual to dose previously treated, unresponsive patients with a short life expectancy in Phase 1, which is where toxicity, safety & dosage outcomes are studied.
Wouldnt want to first test experimental treatments on newly diagnosed or treatment naive patients for fear of severe adverse reactions or risk of life
This is why the preferred patients unfortunately, are the ones with a short life expectancy
That's what I've always thought, too. There're mountains and waterfalls. According to one source I looked at briefly, 94% of the population has drinking water, though there are problems with groundwater contamination in some populated areas.
Janice, as far as I know Sri Lanka is a lush country with lots of rainfall.
There's little point building a windmill when a well would do as well.
https://www.clinicaltrials.gov/ct2/show/NCT02534922?term=prolanta&rank=1
For a DD board, there's not much DD going on here.
This site seems to have a lot of information about water in Sri Lanka. I personally don't think I feel like reading it.
http://slwater.iwmi.org
There's the RAKR PR that bothers me,
http://rainmakerww.com/2017/10/05/sri-lanka-start-bottles-drinking-water-air/
Just think of air as dehydrated water.
I'm aware one CAN, I don't suspect THEY do....just exploring the possibilities as far as rabbit hole depth for the story, guess it depends on how long they want to dump shares
Bullish One, all US clinical drug trials must be in the Clinical Trials Database.
If not, then it is an unregistered, and severely illegal human experimentation.
Is the Oncolix trial in the US Clinical Trials Database ?
SIGO claims to be a MJ company.
They claim revenues.
They never state that the revenue came from MJ.
They 8K harvests, testing, cutting buds and so on.
The filings do show revenue from selling securities.
Why no filings on their MJ revenue?
Would Wade not want to 8K the tons of money SIGO is making from MJ sales?
Those who know his history know he would not miss an opportunity...........
Thoughts anyone?
You can make water from air. That's what your home dehumidifier does.
For example, Rainmaker's brochure say that one of their windmills generates up to 20,000 litres of potable water a day, assuming 80% humidity...
http://rainmakerww.com/wp-content/uploads/2017/09/AW-Product-Sheet-Mar-31-2017-WEB.pdf
LOL, just saw that "company" claims to make drinking water from air.....um....I'll just continue to get mine from the uh, water....
Try https://clinicaltrials.gov
If it's not there, then the company is lying to you.
On RAKR a guy explains to me that the company's PR quoting a Sri Lankan dude which is about to order 12 windmills, cannot possibly be fraudulent, because every PR is checked by numerous regulatory agencies !
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=136538768
Words fail me.
Boy, is this TTTM news confusing
T3 Holdings Inc, T3 Motion Inc., T3M, Inc.,T3MI, T3 Motion, who's who? The "former operations" were purchased. "Under the companys new ownership, (which company?) T3 Motion, has evolved into a well-capitalized, debt free, private operating company" That sounds more like current operations than "former operations." And you can buy stock in private companies on the otc now?
T3 Motion Announces Grand Reopening Under New Ownership & Management Business Wire "Press Releases - English"
T3 Motion to Restart Business Operations December 5, 2017
ONTARIO, Calif. --(BUSINESS WIRE)-- (OTCBB: TTTM) www.t3motioninc.com - T3 Holdings, Inc. , d/b/a T3 Motion, Inc. , today announced its acquisition of the former operations of T3M, Inc. , under a final order of the United States Bankruptcy Court, Central District of California , whereas T3 Holdings, Inc. , acquired essentially all of the assets of the debtor T3MI. The final order of the court was entered on November 27, 2017 .
T3 Motion , originally founded in 2006, pioneered and patented the design of the 3 Wheel Electric Standup Vehicle, used throughout law enforcement and commercial security operations worldwide. To date, T3s are in use by more than 350 domestic and international law enforcement agencies including approximately 50 of the worlds largest international airports.
Under the companys new ownership, T3 Motion , has evolved into a well-capitalized, debt free, private operating company with its manufacturing headquarters located in Ontario, CA , and with a wholly owned Chinese subsidiary, operating in China , building a modified version of its domestic T3 Patroller Series vehicle for distribution throughout Asia .
All U.S. and international customers, outside of Asia , will continue to receive vehicles built exclusively in the United States following the companys long-term commitment to Made in America. The company is also aggressively pursuing its enforcement rights of its large intellectual property portfolio, to stop the unauthorized and illegal manufacturing of Chinese cloned vehicles which have been being offered for sale in mainland China and in some regions of the United States , by previous employees of the company.
T3 Motion , under the management of industry leading professionals, will continue to focus its efforts on providing the highest quality service in the industry, as well as the expansion of the companys leading-edge technologies, into numerous new markets, including the expanding recreational vehicle market.
T3 Motion , as the dominant global manufacturer of Electric Standup Vehicle Technology with an estimated 84% market share, continues to lead the market with its iconic T3 Patroller and new T3 Vision Series vehicles which have been designed and field tested for more than a decade. When it comes to meeting the demands and harsh environments of governmental law enforcement, campus and professional security and patrol operations, clearly, T3 has established itself as the vehicle platform of choice for both indoor and outdoor applications.
About T3 Motion
T3 Motion, Inc. designs, markets and manufactures the T3 Patroller and Vision Series Electric Stand-up Vehicles. Headquartered in Ontario, California , T3 Motion is dedicated to raising the bar on law enforcement and security capabilities in personal mobility technology. More than 5,000 T3 vehicles have been deployed in over 30 countries worldwide. For more information, visit www.t3motioninc.com.
View source version on businesswire.com: www.businesswire.com/news/home/20171130006069/en/
T3 Motion, Inc. Junrong Li (424) 666-4546 www.T3MotionInc.com
Source: T3 Motion, Inc.
Lololol okay good luck :)
lololol. i'll pass. let me know when the are sec reporting.
This isn't a newly formed company. They've been around for 10 years and there are countless publications, studies, and trials in regards to their science. They just went public only this year. There is plenty of solid DD backing their legitimacy. I mean the company has 34 total patents between US and international for Prolanta. And they won't be a Pink sheet for long as they are currently in the process of uplisting to the OTCQB.
Do a little bit of DD before you jump to conclusions. I understand it's easier to be skeptic of OTC companies.
i'll pass on the call. my bet is that this will not be the first stinky pink with a medical breakthrough, but that's just me.
Call GHS/ITOR where the clinical trials are being held. They had tested a lot more than 3 patients but could only bring 3 to completion due short supply of Prolanta. The drug is extremely expensive to manufacture and is probably the driving factor for bringing the company public to have access to more capital and equity. They had burned through $15m+ in venture capital up until this year.
The company lists only 3 patients ...........
that reminds me of the company that was testing cbd oil for medical purposes. they had two patients, the ceo's 8 year old son who had epilepsy or something like that and his grandmother who had arthritis. both reported improvements. the company was suspended and then revoked.
Yes and that peer reviewed published clinical data will be released when the trial has concluded. But even you yourself had a little bit of positive news that you learned about Prolanta through a source that you are unwilling to name. And that has had an impact on you.
The company lists only 3 patients because they only had enough of the drug to bring 3 to completion. The initial phase I had many more than that enrolled and tested on and that was what was told to me by Lisa Johnson who is one the main people overseeing the trial.
But soon we will know as all data will be released at some point in the near future. It's just a waiting game at this point.
This is not that board, this should be posted there.
The company states in their material only 3 patients were dosed and part of the trial.
Using the term "patients conditions were improving" is just more of the same double talk. Clinically define improving? Define how many patients.
You cant so its meaningless really.
See. this is why the medical community adopts standards for providing clinical data. Its also why published, peer reviewed data is required for credibility. Not that I spoke to someone that told me this & that
Okay well maybe efficacy isn't the right word to use if there is a technical component to which is a complete unknown to us at the moment. So for the time being we will just say that patients conditions were 'improving'. There were a lot more than 3 patients enrolled and tested according to Lisa Johnson, and also according to her, all of the patients were 'improving'. Not my words, hers.
SEC Charges Florida Penny Stock Operators With Defrauding Elderly Investors in Push to Crack Down on Repeat Offenders
Miami Office’s Recidivist Initiative Nets 23 Enforcement Actions to Date
FOR IMMEDIATE RELEASE
2017-218
SEC Complaint
https://www.sec.gov/litigation/complaints/2017/comp-pr2017-218.pdf
Washington D.C., Nov. 30, 2017 —
The Securities and Exchange Commission today charged two individuals with defrauding elderly investors in a penny stock scheme involving Florida entertainment companies and their “Spongebuddy” product. The charges are part of the Miami Regional Office’s Recidivist Initiative which has thus far resulted in enforcement actions against 23 individuals, nine of whom also have been charged by criminal authorities.
The SEC’s complaint, filed in U.S. District Court for the Southern District of Florida, charges Joseph A. Rubbo and Angela Beckcom Rubbo Monaco, both of Coral Springs, Florida, with defrauding investors through offerings by their companies VIP TV LLC, VIP Television Inc., and The Spongebuddy LLC. Rubbo and Monaco are repeat offenders whose prior securities schemes resulted in criminal convictions against Rubbo and SEC injunctions against both Rubbo and Monaco.
The U.S. Attorney’s Office for the District of Colorado has filed parallel criminal charges against Rubbo, Monaco, Steven J. Dykes, and others relating to the scheme.
According to the SEC’s complaint, Rubbo and Monaco raised at least $5.4 million from 11 primarily elderly investors to fund the growth of their entertainment business and develop the Spongebuddy, a sponge-like glove purportedly to be sold in stores.
The SEC’s complaint alleges that Rubbo and Monaco controlled the companies and hired Dykes to cold call investors and pitch investments in VIP. For example, Dykes allegedly told an investor that the Starz cable channel and Pandora Radio were both interested in buying VIP and would “roll-up” VIP into these entities. The investor also was allegedly told that the Spongebuddy would be featured on the television show “Shark Tank” and marketed on QVC. Contrary to alleged representations that investor money would be used to benefit the VIP companies, Rubbo and Monaco misappropriated more than $2.6 million in investor funds to pay themselves and their relatives as well as undisclosed sales commissions to Dykes. The complaint also alleges they paid for personal expenses such as the down payment on a luxury vehicle, credit card bills, unrelated construction work and to finance a business operation for a Monaco family member.
“As alleged in our complaint, Rubbo and Monaco defrauded investors by stealing millions of dollars from elderly investors which they spent on themselves and their family members instead of investing in their businesses,” said Steven Peikin, Co-Director of the SEC’s Enforcement Division. “Both Rubbo and Monaco were caught through the efforts of the Miami Regional Office’s Recidivist Initiative, which is part of our ongoing focus to rid the markets of repeat securities law violators.”
During the time of the alleged scheme, neither Rubbo, Monaco, nor Dykes were registered with the Commission. The SEC encourages all investors to check the background of people selling investments by using the search tool on Investor.gov to quickly identify whether the sellers are registered professionals.
The SEC’s complaint charges Rubbo and Monaco with violating the antifraud provisions of the federal securities laws. The SEC also charged Dykes with violating the broker-dealer registration provisions, and Rubbo and Monaco with aiding and abetting violations by Dykes. The SEC is seeking the return of the defendants’ allegedly ill-gotten gains with interest, monetary penalties, a permanent injunction, and other relief.
The SEC’s investigation, which is continuing, is being conducted by Linda S. Schmidt and Lina M. Fernandez in the Miami Regional Office. The case is being supervised by Jason R. Berkowitz and the SEC’s litigation is being led by Christine Nestor. The SEC appreciates the assistance of Florida’s Office of Financial Regulation.
###
https://www.sec.gov/news/press-release/2017-218
Efficacy is defined by tumor regression or stabilization, in this case. That regression/stabilization, if any, must be categorized by Recist standards, not in a generally speaking way as is the case here.
The specific data points must also be analyzed... did tumor regression or stabilization occur in 1, 2 or 3 patients? What period of time did the tumors remain in regression/stabilization or did they develop resistance and revert to progressing etc?
Theres a lot of data points that require analyzing before responsibly making such a statement. In fact, one patients tumor may have stabilized for 2 days and then progressed...Thats evidence of efficacy but its meaningless.
Additionally, publication and peer review is required to establish credibility. The efficacy claim being discussed here has not
Im not saying Prolanta is a bust. Just not enough info to run around claiming evidence of efficacy and be taken seriously yet
The other thing that is intriguing about Oncolix is the fact that Ernest Mario is invested in the company. Ernest Mario is the former CEO of GlaxoSmithKline GSK.
Also, the inventor of Prolanta, Wen Chen, also invented Somavert, which is a drug that gained FDA approval, for people who have HGH disorders, for Pfizer.
Somavert, which is known as G120R, is a growth hormone receptor antagonist. This drug was able to successfully inhibit growth hormone receptors to help patients who have growth hormone disorders.
Prolanta, which is also known as G129R, is Wen Chens other invention. He developed both G120R and G129R around the same time period using the exact same amino acid substitution method. These drugs are almost identical to each other. The other interesting fact is that the structure of prolactin is similar to that of growth hormone and placental lactogen.
So here you have 2 identical drugs that are antagonists for 2 hormones that are very structurally similar to each other. Inhibiting human prolactin may be effective in antitumor activity because of its role in the presence and growth of cancerous tumors. The other issue with human prolactin hormones is that they also contribute to humans becoming resistant to chemotherapy. If you can antagonize the human prolactin receptors and hormone, you can at the very least increase the efficacy of chemotherapy, which in itself would be a major breakthrough.
So in conclusion, knowing that we have 2 almost identical drugs working to antagonize structurally similar hormones, we can hypothesize that both would be almost equally effective. One drug, Somavert, has already achieved FDA approval, and the other drug, Prolanta, has a strong probability to follow suit.
Here's an article that contains information regarding the similarities of the prolactin hormone and growth hormone:
https://link.springer.com/chapter/10.1007%2F978-1-4757-3600-7_7
They are both pituitary hormones with structural similarities. Somavert was able to become a successful antagonist to HGH and Prolanta is a nearly identical drug and will more than likely be a successful antagonist to PRL.
Successful antagonism of PRL doesn't guarantee antitumor activity as a monotherapy, but knowing PRL's role in cancer patients resistance to chemo, it's almost guaranteed to improve the efficacy of the chemo, which would be a major breakthrough.
What we do know, based on what Redman has said and also what Lisa Johnson told me over the phone when I called GHS/ITOR, is that Prolanta, as a monotherapy, is showing efficacy.
More EFLN hilarity, from Ljubica on yahoo.....
THE EFLN EXPANDING BUSINESSE into INTERNATIONAL MARKETS WITH HELP FROM EUROPIAN STATE AND SRBIJAN C0MPANY . EFUEL EFN CORP. CAN HAVE MILLIONS US. DOLLARS IN SALES IN THE 2018.
But either way, you can call the clinic where the Oncolix trials are taking place and they will tell you that in the initial phase I, efficacy was observed as in anti-tumor activity. So it's a statement that holds truth and theres no way around it. Observing efficacy in phase I is just a bonus on top of what is the main purpose of phase I, which is to find out the safety and tolerability of the drug.
Well there's one study that was done regarding their drug and it's efficacy where they were tested it in vivo in orthotopic model. Tumor weights were reduced by 50% as a monotherapy and 90% when used in conjunction with chemotherapy. This study as also talks about the method of action by G129R which is known as autophagy (programmed cell death). Autophagy made headlines in 2016 as a scientist was awarded the Nobel Prize for his work and discoveries with autophagy.
Here is the link to the Oncolix study regarding G129R dated back in 2014: http://d-scholarship.pitt.edu/24726/1/1-s2.0-S2211124714001879-main.pdf
They certainly weren't trying to pump any stock back in 2014 when they just went public this year. At least I don't think they were.
DD Support Board and Fraud Research Forum
This forum is a place for ALL to share and build research and due diligence.
This is not a forum for recommending stocks to buy or sell. It is for information sharing only.
Please do not use this forum to promote stocks.
Feel free to build on the research already done by others or to present fresh new research.
Please start all informational posts with the ticker symbol of the stock.
Important links:
Another place to read some of nodummy's research:
http://promotionstocksecrets.com/
Great Forum for Litigation and Court Docket updates not posted on this board:
www.investorshub.advfn.com/boards/board.aspx
SEC trading suspensions:
http://www.sec.gov/litigation/suspensions.shtml
SEC press releases:
http://www.sec.gov/news/press.shtml
SEC administration proceedings:
http://www.sec.gov/litigation/admin.shtml
SEC litigation releases:
http://www.sec.gov/litigation/litreleases.shtml
Most recent SEC flings:
http://www.sec.gov/cgi-bin/browse-edgar?company=&CIK=&type=&owner=exclude&count=40&action=getcurrent
Great Website for basic information about the laws surrounding penny stocks
http://www.securitieslawyer101.com
Stock Dilution Scam:
A share dilution scam happens when a company, typically traded in unregulated markets such as the OTC Bulletin Board and the Pink Sheets, repeatedly issues a massive amount of shares into the market for no reason, considerably devaluing share prices until they become almost worthless, causing huge losses to shareholders. Then, after share prices are at or near the minimum price a stock can trade and the share float has increased to an unsustainable level, those fraudulent companies tend to reverse split and continue repeating the same scheme.
Pump and Dump Schemes:
"Pump and dump" schemes, also known as "hype and dump manipulation," involve the touting of a company's stock (typically microcap companies) through false and misleading statements to the marketplace. After pumping the stock, fraudsters make huge profits by selling their cheap stock into the market.
Pump and dump schemes often occur on the Internet where it is common to see messages posted that urge readers to buy a stock quickly or to sell before the price goes down, or a telemarketer will call using the same sort of pitch. Often the promoters will claim to have "inside" information about an impending development or to use an "infallible" combination of economic and stock market data to pick stocks. In reality, they may be company insiders or paid promoters who stand to gain by selling their shares after the stock price is "pumped" up by the buying frenzy they create. Once these fraudsters "dump" their shares and stop hyping the stock, the price typically falls, and investors lose their money.
http://www.sec.gov/answers/pumpdump.htm
The key is understanding
The key is understanding that pink sheet stocks are not investments - 99% of them will lose value over the long run and never accomplish most of their forward looking pumping statements they put in press releases or on their websites. Never believe the hype - always be skeptical of everything you hear.
The people mostly making money with pink sheet stocks are promoters, front loading pumpers with big followings they can dump on, crooks, some of the flippers, and sometimes the very lucky.
Pumpers only tell you to buy stocks that they already own. Pumpers only tell you to hold stocks because they want to make sure you hold longer than them.
They make money by pumping the stock and getting other people to buy then dumping their shares on the followers.
If you really want to take the risk of trying to make money trading pink sheet companies then you have to understand how the game works and never ever hold long term - take profits when you can. Pump and Dumps dominate the IHUB forums.
Trading pink sheet stocks is a sick game full of lies and deceit where people take advantage of the inexperienced and naive stealing away their life savings for their own personal gains.
Very little respect or morals exist in stinky pinky land.
The Consequences of an SEC Suspension:
Complete list of SEC suspended stocks and SEC Admin. Law Judge registration revocations from January 1st, 2010 to May 9,2020:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=155531213
More information on Suspended Stocks
http://investorshub.advfn.com/SEC-Suspensions-&-Revocations-25334/
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |